Skip to content

Study Comparing EBUS & EUS to Mediastinoscopy in Staging and Detection of Lung Cancer

A Prospective Multicenter Study Comparing Endobronchial and Endoscopic Ultrasound-Guided FNA to Mediastinoscopy/Thoracoscopy in the Staging and Early Detection of Metastases in Lung Cancer

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00970645
Enrollment
2
Registered
2009-09-02
Start date
2010-02-28
Completion date
2011-03-31
Last updated
2011-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Keywords

Non small cell lung cancer, mediastinum, endobronchial ultrasound fine needle aspiration, endoscopic ultrasound, mediastinoscopy, surgical or minimally invasive evaluation of mediastinum, NSCLC

Brief summary

This is a prospective randomized clinical trial with the study cohort comprised of all male and female patients over the age of 21 presenting to the study site for evaluation of lung cancer. The study will enroll 300 subjects, with 150 in each arm. Three sites will be in the study, Mayo Rochester, Mayo Jacksonville and Medical University of South Carolina. Mayo Rochester will enroll approximately 125 subjects. This study does not require subjects to undergo any additional procedures than what they would receive per standard medical care. The consenting subjects will receive EUS and /or EBUS- guided FNA or Mediastinoscopy/Thoracoscopy.

Detailed description

This is a prospective randomized clinical trial of males and females age 21 or older being evaluated for lung cancer. The study will enroll approximately 300 subjects (150 in each arm) at 3 participating centers (MUSC, Mayo Clinic Rochester and Jacksonville). This sample size will provide sufficient statistical power (i.e. \>80%) using a non-inferiority study design with 1-sided hypothesis testing (Farrington and Manning 1990) to determine whether or not the sensitivity of the EUS/EBUS diagnostic technique is inferior (i.e. 10% or more lower) when compared to the sensitivity of malignant mediastinal adenopathy of about 40%. This study requires subjects to agree to the selection of their standard of care procedure. Subjects will be randomized (stratified computer generated randomization stratified y center and y CT positivity for pathologically enlarged \[\>1cm short axis\] node - 10 strata). Randomization will use variable block sizes (4-8), so that randomization allocation remains concealed as investigators will not be blinded. This study requires subjects to consent to the release of outcome data and follow-up data to be used for study analysis. No additional visit will be required for this study; this study will not require any additional time requirements beyond their scheduled evaluations.

Interventions

PROCEDUREMediastinoscopy/thoracoscopy

Mediastinoscopy used to detect/stage lung cancer.

PROCEDUREEBUS/EUS

Minimal invasive technique to stage/detect lung cancer.

Sponsors

Medical University of South Carolina
CollaboratorOTHER
Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 21 years or greater * Pt is a surgical candidate for mediastinoscopy, thoracoscopy, or lung resection * Known or suspected non-small cell carcinoma of the lung eligible for resection * CT scan performed within 45 days prior to evaluation for study participation * PET scan performed within 45 days prior to evaluation for study participation

Exclusion criteria

* Pathologically proven metastatic disease * History of malignancy within 5 years other than (skin) basal cell carcinoma * Enlarged ipsilateral mediastinal lymph nodes \> 2.5 cm in diameter * Peripheral T1 tumors with normal mediastinal lymph nodes on CT and PET

Design outcomes

Primary

MeasureTime frame
Develop an integrated staging technique to detect early metastases in lung cancer which should affect patient outcomes more accurately than conventional staging techniques.Post operative

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026